Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer

Targeted Oncology

Volumn 6, Issue 3, 2011, Pages 171-180

  Sacco, Paola Claudia ^a   Maione, Paolo ^a   Rossi, Antonio ^a   Bareschino, Maria Anna ^a   Schettino, Clorinda ^a   Guida, Cesare ^a   Elmo, Massimo ^a   Ambrosio, Rita ^a   Barbato, Valentina ^a   Zeppa, Rosario ^a   Palazzolo, Giovanni ^b   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b S G Moscati Hospital ^*  (Italy)

Author keywords

Chemotherapy; Locally advanced NSCLC; Radiotherapy; Targeted therapy

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; L BLP 25; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; TG 4010; UNCLASSIFIED DRUG; VINBLASTINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; AREA UNDER THE CURVE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DERMATITIS; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG ERUPTION; ERADICATION THERAPY; ESOPHAGITIS; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; HYPOXIA; INFECTION; LOADING DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK REDUCTION; STANDARD; STOMATITIS; SURVIVAL RATE; THERAPY EFFECT; THORAX PAIN; TREATMENT DURATION; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY;

EID: 79960356090     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0169-6     Document Type: Review

References (79)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA. Cancer J Clin 59:225-249
2. Mountain CF (1997) Revisions in the international system for staging lung cancer. Chest 111:1710-1717 (Pubitemid 27260107)
3. Rosell R (1998) The integration of newer agents into neoadjuvant therapy. Semin Oncol 25(suppl 8):24-27 (Pubitemid 28371490)
4. Gandara DR, Lara PN Jr, Goldberg Z, Roberts P, Lau DH (2001) Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs 12(suppl 1):S5-S9 (Pubitemid 32269907)
5. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909
6. Jett JR, Schild SE, Keith RL, Kesler KA (2007) Treatment of non small cell lung cancer, stage III B. Chest 132:266S-276S
7. Blackstock AW, Govindan R (2007) Definitive chemoradiation for the treatment of locally advanced non small- cell lung cancer. J Clin Oncol 25:4146-4152 (Pubitemid 47492959)
8. Gervais R, Ducolone A, Lechevalier T et al (2005) Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) vinorelbine (Vr)-cisplatine (P): final results of a randomized phase III trial in stage III unresectable non small cell lung (NSCLC) cancer: study CRG/ BMS/NPC/96 of the French Lung Cancer Study Group FNCLCC and IFCT (Abstract). J Clin Oncol 23:7016
9. Zatloukal P, Petruzelka L, Zemanova M et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46:87-98 (Pubitemid 39201387)
10. Huber RM, Flentje M, Schmidt M et al (2006) Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB nonsmall- cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24:4397-4404 (Pubitemid 46630977)
11. Clamon G, Herndon J, Cooper R et al (1999) Radiosensitization with carboplatin for patients with unresectable stage III non-smallcell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 17:4-11 (Pubitemid 29022371)
12. Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique- Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23:5910-5917
13. Curran WJ, Scott C, Langer CJ et al (2003) Long-term benefits is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresectable stage III NSCLC: RTOG 9410 (Abstract 2499). Proc Am Soc Clin Oncol 22:621
14. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17:2692-2699 (Pubitemid 29415225)
15. Belani CP, Choy H, Bonomi P et al (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23:5883-5891
16. Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB nonsmall cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004-2010 (Pubitemid 46606390)
17. Meert AP, Paesmans M, Martin B et al (2002) The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 87:694-701 (Pubitemid 35178743)
18. Fontanini G, Lucchi M, Vignati S et al (1997) Angiogenesis as a prognostic indicator of survival in non-small-cell carcinoma: a prospective study. J Natl Cancer Inst 89:881-886 (Pubitemid 27268454)
19. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23:3243-3256 (Pubitemid 46211349)
20. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027 (Pubitemid 46202320)
21. Jain RK, Duda DG, Clark JW et al (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40 (Pubitemid 43108832)
22. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2:727-739 (Pubitemid 37328908)
23. Ferrara N, Hillan KJ, Gerber HP et al (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400 (Pubitemid 38618122)
24. Sandler AB, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
25. Manegold C, von Pawel J, Zatloukal P, the BO17704 Study Group et al (2007) Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy- naïve patients with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 25(Suppl):LBA7514
26. Herbst RS, Shin DM (2002) Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593-1611 (Pubitemid 34212655)
27. Barbender J, Danenberg KD, Metzger R et al (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in nonsmall cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855 (Pubitemid 32994816)
28. Mendelsohn J (2001) The epidermal growth factor as a target for cancer therapy. Endocr Relat Cancer 8:3-9 (Pubitemid 32520250)
29. Fontanini G, De Laurentiis M, Vignati S et al (1998) Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-smallcell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 4:241-249 (Pubitemid 28062903)
30. Rusch V, Klimstra D, Venkatraman E et al (1997) Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515-522 (Pubitemid 27211827)
31. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factorrelated peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
32. Ritter CA, Arteaga CL (2003) The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 30(Suppl 1):3-11 (Pubitemid 36307612)
33. Ross JS, Schenkein DP, Pietrusko R et al (2004) Targeted therapies for cancer 2004. Am J Clin Pathol 122:598-609 (Pubitemid 39281258)
34. Sequist LV, Lynch TJ (2008) EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 59:429-442 (Pubitemid 351287947)
35. Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non small cell lung cancer. J Clin Oncol 23:3235-3242 (Pubitemid 46211348)
36. Shepherd FA, Pereira J, Ciuleanu TE et al (2005) Erlotinib in previously treated non small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
37. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 24:3831-3837 (Pubitemid 46630729)
38. Clark GM, Zborowski DM, Santabarbara P, Ding K, Whitehead M, Seymour L et al (2006) Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non small cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 7:389-394 (Pubitemid 44043548)
39. Cappuzzo F, Coudert B, Wierzbicki R et al (2009) Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC). Eur J Cancer Suppl 7(3):12 (abstr 22LBA)
40. European Medicines Agency. Press Release, 19 March 2010. http://www.ema.europa.eu/pdfs/human/press/pr/10757010en.pdf
41. FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer. http://www.gene.com/gene/news/ press-releases/display.do?method= detail&id=12727
42. Rosell R et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967
43. Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
44. Mendelsohn J (1997) Epidermal growth factor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3:2703-2707 (Pubitemid 28133130)
45. Goldstein NI, Prewett M, Zuklys K et al (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (11):1311-1318
46. Li S, Schmits KR, Jeffrey PD et al (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301-311 (Pubitemid 40544648)
47. Zhang W, Gordon M, Schultheis AM et al (2006) Two immunoglobulin G fragment C receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal patients treated with single agent cetuximab. J Clin Oncol 24(18S):Abstract 3028
48. Raben D, Helfrich B, Chan DC et al (2005) The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11:795-805 (Pubitemid 40116908)
49. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non small-cell lung cancer (FLEX): an open label randomized phase III trial. Lancet 373:1525-1531
50. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252 (Pubitemid 28155090)
51. Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042-1049
52. Ribas A, Butterfield LH, Glapsy JA et al (2003) Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 21:2415-2432 (Pubitemid 46621880)
53. Peat N, Gendler SJ, Lalani N et al (1992) Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res 52:1954-1960
54. Vlad AM, Kettel JC, Alajez NM et al (2004) MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 82:249-293 (Pubitemid 38209513)
55. Butts C, Murray N, Maksymiuk A et al (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV nonsmall- cell lung cancer. J Clin Oncol 23:6674-6681 (Pubitemid 46190262)
56. Butts C, Maksymiuk A, Goss G et al (2007) A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (LBLP25 or Stimuvax) for active specific immunotherapy of nonsmall cell lung cancer (NSCLC): updated survival analysis. J Thor Oncol 2(suppl 4):S332-S333 (abstr. B1-01)
57. Ramlau R, Quoix E, Rolski J et al (2008) A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer. J Thor Oncol 3:735-744
58. Ramlau R, Westeel V, Papai Z et al (2008) Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1- IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26(15S):429s (abstr 8023)
59. http://www.drugs.com/clinical-trials/transgene-s-therapeuticvaccine- tg4010-promising-additional-clinical-data-non-small-celllung- 5528.html. Accessed June 10, 2009
60. Sienel W, Varwerk C, Linder A et al (2004) Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg 25:131-134 (Pubitemid 38019071)
61. Vansteenkiste J, Zielinski M, Linder A et al (2007) Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 25(18S):398s (abstr 7554)
62. Vansteenkiste J, Zielinski M, Dahabreh IJ et al (2008) Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 26(15S):397s (abstr 7501)
63. Baumann M, Krause M, Dikomey E, Dittmann K, Dörr W, Kasten-Pisula U, Rodemann HP (2007) EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83(3):238-248 (Pubitemid 46915540)
64. Dent P, Yacoub A, Contessa J et al (2003) Stress and radiationinduced activation of multiple intracellular signaling pathways. Radiat Res 159:283-300 (Pubitemid 36314943)
65. Liang K, Ang KK, Milas L, Hunter N, Fan Z (2003) The epiderma growth factor receptor mediates radioresistance. Int JRadiat Oncol Biol Phys 57:246-254 (Pubitemid 36959763)
66. Bentzen SM, Atasoy BM, Daley FM et al (2005) Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23:5560-5567
67. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578 (Pubitemid 43209104)
68. Blumenschein G, Moughan J, Curran W et al (2007) A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324 trial. J Clin Oncol (2007 ASCO Annual Meeting Proceedings Part I) 25:18S (June 20 Supplement): 7531
69. Hughes S, Liong J, Miah A et al (2008) A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH Study. J Thorac Oncol 3:648-651 (Pubitemid 351787311)
70. Govidan R, Bogart X, Wang L et al (2009) Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable nonsmall cell lung cancer: CALGB 30407. J Clin Oncol 27:15s (suppl;abstr 7505)
71. Ready N, Janne P, Herndon J et al (2006) Chemoradiotherapy and Gefitinib in stage III non-small cell lung cancer(NSCLC): a CALGB stratified phase II trial. J Clin Oncol 24(18S):7046
72. Ball D, Burmeister B, Mitchell P et al (2007) Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non small cell lung cancer ("CRITICAL"). J Thor Oncol 2(8):S633-S634
73. Ohe Y, Nishiwaki Y et al (2010) Safety and efficacy trial of cisplatin with vinorelbine followed by gefitinib and concurrent thoracic radiotherapy for unrectable locally advanced non small cell lung cancer: Japan Clinical Oncology Group (JCOG) 0402. J Clin Oncol 28:15s, abstr 7084
74. Martinez E, Martinez M, Vinolas N et al (2008) Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients with unresectable NSCLC: a prospective randomized phase II study. J Clin Oncol 26(May 20 suppl):abstr 7563
75. Gorski DH, Beckett MA, Jaskowiak NT et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378 (Pubitemid 29334495)
76. Hartford AC, Gohongi T, Fukumura D et al (2000) Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. Cancer Res 60:2128-2131 (Pubitemid 30225172)
77. Sonveaux P, Brouet A, Havaux X et al (2003) Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 63:1012-1019 (Pubitemid 36278432)
78. Teicher BA, Depuis NP, Kusumoto T et al (1995) Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Investig 2:269-276
79. Socinski MA, Stinchcombe TE, Halle JS et al (2009) Incorporation of bevacizumab and erlotinib with induction and concurrent carboplatin/paclitaxel and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 27:15s (suppl;abstr 7528)